Cambridge Cognition Sees Strong Orders Momentum Build

Highlights

• New sales activity strengthens sharply across markets

• Order book expands, supporting future visibility

• Financial position improves with reduced borrowing pressure

Cambridge Cognition reports a notable rise in new sales orders, a stronger order pipeline, and improved financial stability despite earlier revenue pressure, supported by cost discipline and market expansion.

Growing Momentum Across Core Business Areas

Cambridge Cognition Holdings plc (LSE:COG), a neuroscience technology business, has reported a clear improvement in commercial activity, driven by stronger demand across its core clinical and research-focused solutions. The latest update highlights a significant rebound in new sales orders, supported by expanding engagement across multiple healthcare-related segments.

The business operates within the evolving intersection of neuroscience, digital health, and cognitive assessment technologies. Its solutions are widely used in clinical trials, academic research, and increasingly in healthcare and wellness applications, where digital tools are becoming more integrated into patient monitoring and behavioural analysis.

Despite earlier pressure on revenue performance due to a weaker starting backlog, the company has demonstrated a meaningful recovery in sales activity, suggesting improved commercial traction and stronger engagement with clients across its operating markets.

Strong Recovery in New Business Activity

A key feature of the latest update is the substantial rise in new sales orders, reflecting renewed demand across both established and emerging business areas. This improvement indicates stronger conversion of pipeline opportunities and a broader acceptance of digital cognitive assessment tools across healthcare and research environments.

The increase in orders signals a shift in business momentum, as earlier constraints linked to backlog conditions begin to ease. This has allowed the company to rebuild its commercial foundation and strengthen forward-looking visibility.

The expansion in the order pipeline also suggests growing confidence among customers operating in clinical studies, academic institutions, and healthcare innovation sectors. These segments continue to adopt digital technologies for more efficient data collection and cognitive performance analysis.

Expanding Order Book Supports Future Visibility

Alongside stronger sales activity, the company has reported an expansion in its order book, which provides improved visibility over future revenue streams. A larger order book typically reflects confirmed contracts and ongoing engagements that are expected to convert into recognised business activity over time.

This strengthening order pipeline is particularly important in sectors such as neuroscience technology, where project-based work and long-term research contracts form a core part of revenue generation.

The growing order book also demonstrates that demand is not limited to a single area of the business. Instead, progress is being seen across multiple segments, including clinical research, academic studies, professional healthcare applications, and consumer-focused wellness solutions.

This diversification is helping the business reduce reliance on any single market and broaden its addressable opportunity base.

Revenue Pressure and Operational Discipline

While sales orders and pipeline strength have improved, revenue performance has reflected earlier challenges linked to a weaker starting position. The initial backlog condition contributed to softer revenue recognition during the period, which influenced overall financial output.

However, operational discipline has played a key role in managing the impact of this transition phase. Cost control measures introduced earlier have helped limit the effect on underlying performance, ensuring that the business maintains a more stable financial structure despite revenue fluctuations.

This combination of disciplined cost management and improving commercial activity suggests that the business is transitioning through a recovery phase, where order inflows are strengthening ahead of revenue recognition.

Improving Financial Position and Capital Structure

The company has also made progress in strengthening its financial position. Improved cash management, combined with reduced borrowing levels, has contributed to a more balanced capital structure.

A previous period of cash outflow has shifted toward a more stable position, supported by improved operational cash generation. This transition is important for maintaining flexibility in funding ongoing research, product development, and market expansion initiatives.

Borrowing levels have also reduced, reflecting a deliberate effort to strengthen the balance sheet. This reduction in leverage supports greater financial stability and positions the business more effectively for future growth phases.

The overall financial improvement reflects a combination of capital raising activity and stronger operational discipline, helping to stabilise liquidity conditions and reduce dependency on external funding sources.

Expansion Across Multiple Market Segments

Cambridge Cognition continues to expand its presence across four key market segments, reinforcing its position within the cognitive assessment and neuroscience technology space.

These segments include:

• Clinical research and drug development studies

• Academic neuroscience and cognitive science research

• Professional healthcare applications

• Consumer health and wellness technologies

The expansion into professional healthcare and consumer wellness reflects a broader strategic shift toward more diversified applications of cognitive assessment tools. These areas are increasingly influenced by digital transformation trends, where data-driven insights are becoming essential for personalised care and behavioural analysis.

This diversification supports long-term business resilience by broadening the range of customers and use cases for its technology platform.

Industry Context and Market Positioning

The broader environment for neuroscience technology continues to evolve, driven by increased adoption of digital health tools, remote clinical trials, and data-centric healthcare models.

Within this context, Cambridge Cognition is positioned at the intersection of research innovation and applied healthcare technology. Its solutions are designed to support cognitive measurement and analysis across a wide range of use cases, from early-stage clinical trials to ongoing patient monitoring.

The business operates within a competitive but expanding ecosystem, where demand for digital cognitive tools is being shaped by advances in healthcare digitisation and growing interest in mental health and cognitive performance tracking.

Future Outlook and Growth Direction

Looking ahead, the company expects continued improvement in revenue performance, supported by its strengthened order book and ongoing commercial activity.

While earlier revenue levels reflected a weaker starting position, current momentum in new sales activity suggests a more supportive environment for future growth. The combination of expanding pipeline visibility and diversified market exposure provides a foundation for improved financial outcomes.

Further sales activity expected during the ongoing period is not yet fully reflected in current forward expectations, indicating additional upside from continued commercial execution.

The business outlook is shaped by:

• Strengthening demand across healthcare and research markets

• Expansion into new application areas

• Improved financial stability and reduced borrowing pressure

• Increasing integration of digital cognitive tools in clinical workflows

Role Within Broader UK Market Landscape

The company operates within the wider UK equity environment, which includes technology-driven healthcare innovators listed across different market segments.

Relevant market frameworks include:

• LSE & FTSE stock market ecosystem supporting listed innovation-led companies

• FTSE 100 benchmark representing large-cap market leaders

• FTSE 350 reflecting mid- and large-cap market activity

• FTSE AIM 50 capturing emerging growth-oriented companies

Within this structure, Cambridge Cognition represents a specialised technology business focused on neuroscience-driven digital solutions, contributing to the broader innovation segment of UK-listed companies.

Strategic Direction and Market Expansion

The company’s recent performance highlights a gradual transition toward broader market participation. Expansion beyond traditional clinical research into healthcare and wellness applications indicates an evolving strategy focused on scalability and diversification.

This direction is aligned with global trends in healthcare innovation, where cognitive data, digital assessments, and remote monitoring tools are increasingly integrated into standard care and research workflows.

As adoption increases across these areas, the company’s platform-based approach provides opportunities to serve a wider customer base while maintaining strong relevance in core research markets.

Cambridge Cognition Holdings plc (COG) has demonstrated a meaningful improvement in commercial momentum, supported by stronger new sales activity, an expanding order book, and improved financial stability. While earlier revenue conditions reflected a weaker starting position, recent developments indicate a shift toward recovery and renewed growth direction.

With diversified market expansion, improved balance sheet strength, and growing demand across healthcare and research sectors, the business appears positioned for a more stable operational phase supported by stronger forward visibility.